Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2017-10-12
2025-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
NCT00404820
Efficacy of Oral Ibandronate in Osteoporosis
NCT03186131
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
NCT00097825
Zoledronic Acid for Osteoporosis in the Elderly
NCT00558012
Zoledronic Acid in MS-patients With Osteoporosis
NCT01166178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ZA alone
"Zoledronic acid", "Reclast®"
To examine the efficacy of zoledronic acid in osteoporosis
ZA plus VD
"Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®"
To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"Zoledronic acid", "Reclast®"
To examine the efficacy of zoledronic acid in osteoporosis
"Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®"
To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who are pregnant or breast-feeding
* Patients who have not taken zoledronic acid for the last 2 years
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shinshu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yukio Nakamura
Associate professor at Shinshu University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yukio Nakamura
Matsumoto, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Zol2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.